Crossmark

ASO Author Reflections: Is PET/CT Response Assessment After Neoadjuvant Systemic Therapy for Stage III Melanoma Enough?

Published Online: 2025-08-29

Authors

Stoff, Ronen https://orcid.org/0000-0002-4796-9148
Block, Matthew S.

Hieken, Tina J.
License Information

Text and Data Mining valid from 2025-08-29

Version of Record valid from 2025-08-29
More Information

Article History

Received: 13 August 2025

Accepted: 13 August 2025

First Online: 29 August 2025

Disclosure

: Matthew Block has received institutional research support from Alkermes, Bristol-Myers Squibb, Genentech, Merck, nFerence, Perspective Therapeutics, Pharmacyclics, Regeneron, Sorrento, TILT Biotherapeutics, and Transgene, and is an (unpaid) consultant for Sorrento Therapeutics, TILT Biotherapeutics, and Perspective Therapeutics. Tina Hieken has received research funding, paid to her institution, from Genentech and SkylineDx. Ronen Stoff has no disclosures to declare that may be relevant to the contents of this study.

Document is current